S ince the publication of 5 seminal randomized clinical trials comparing mechanical thrombectomy (MT) with best medical therapy in 2015, [1] [2] [3] [4] [5] treatment for intracranial large vessel occlusion with stent retrievers has become standard of care and has been endorsed by various guidelines around the world ≤6 hours from symptom onset. 6, 7 These trials varied in their inclusion criteria, time windows, and imaging protocols, and 4 of the trials were stopped before the enrollment targets were reached because of efficacy. A patient-level prespecified pooled meta-analysis of 4 randomized clinical trials which used the Solitaire stent retriever as the first device (Safety and Efficacy in Solitaire Stent Thrombectomy or SEER 8 ) in 401 patients in the intervention arm has been published, providing Level 1 evidence regarding the use of this device in a clinical trial setting.
The goal of the STRATIS registry (Systematic Evaluation of Patients Treated with Neurothrombectomy Devices for Acute Ischemic Stroke) was to prospectively analyze the results of MT within the Food and Drug Administration 510(k) approval window of 8 hours for intracranial large vessel occlusion in a real world setting without additional restrictions on imaging protocols or technique. The protocol was designed to capture detailed information on system of care factors, process times, and technique and correlate them with imaging and clinical outcomes at 90-day follow-up. In addition, a comparison to a similar cohort, the SEER intervention arm (SWIFT PRIME, ESCAPE, EXTEND-IA, REVASCAT), was undertaken to reference the results of STRATIS against those of the randomized clinical trials.
Methods

Study Design and Inclusion Criteria
The STRATIS registry was a prospective, multicenter, nonrandomized, observational registry evaluating the use of Solitaire Revascularization Device (Solitaire) and Mindframe Capture Low Profile Revascularization Device (Mindframe) in patients experiencing an acute ischemic stroke because of large intracranial vessel occlusion. The registry was designed to enroll 1000 patients at ≤60 academic and nonacademic US sites with the following eligibility criteria: (1) any confirmed large intracranial vessel occlusion with associated symptoms, (2) intention to be treated with a Medtronic market-released neurothrombectomy device as the initial device to remove thrombus, (3) treatment within 8 hours of stroke onset, (4) modified Rankin Scale (mRS) score ≤1 prior to stroke onset, (5) pretreatment National Institutes of Health Stroke Scale (NIHSS) score ≥8 and ≤30, and (6) not participating in a multicenter randomized clinical trial. Patients were consented for participation ≤7 days postprocedure or hospital discharge (whichever came first). Site enrollment was capped at 75 patients to ensure inclusion of patients from a diverse group of centers and prehospital systems. No additional requirements on center volume, workflow, or imaging selection were specified. Cranial DICOM imaging (Digital Imaging and Communications in Medicine) was centrally collected and interpreted by an independent imaging core laboratory for site of occlusion, modified Thrombolysis in Cerebral Infarction (mTICI), and Alberta Stroke Program Early CT Score. 9, 10 The SWIFT PRIME (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment) definitions for puncture, symptomatic intracranial hemorrhage (sICH), and vessel segments were applied. 1 A technique core laboratory reviewed procedural reports and classified procedural technique. All subjects with a known neurological deterioration between enrollment and discharge were adjudicated by a Clinical Events Committee for primary cause of neurological deterioration. The definitions of the time metrics reported are included in Table I in the online-only Data Supplement. The protocol was approved by the local institutional review boards.
Outcome Measures
The primary outcome was defined as the severity of disability as assessed by mRS score at 90 days postprocedure. Secondary outcome measures included prehospital and hospital workflow times, such as time from door to puncture (DTP) and time from puncture to reperfusion (PTR). Reperfusion was defined as mTICI ≥2b, assessed by both site and independent imaging core laboratory using the mTICI grading scale. 10 Safety evaluations included incidence of neurological *The protocol was amended to restrict enrollment to mRS 0-1 to ensure consistency with SWIFT PRIME enrollment criteria. †Baseline imaging received for 835 patients. Of which, 72 were not evaluated for ASPECTS (38 posterior stroke, 30 no noncontract CT, 4 not evaluable), resulting in 763 patients evaluable for ASPECTS.
‡For STRATIS, assessed by the Techniques Core Laboratory based on operative reports.
deterioration events, sICH, all-cause mortality, and incidence of device-and procedure-related serious adverse events up to 90 days postindex stroke procedure. A patient-level comparison with the SEER database was performed. Subgroup analyses were performed based on age, 6 to 8 hours treatment window, distal occlusion location, use of perfusion imaging, and tandem occlusion.
Statistical Analysis
Descriptive statistics were used to present the data using the mean, standard deviation, and median with interquartile range or frequency distribution as appropriate. For 2-group comparisons, t tests or the Wilcoxon rank-sum test was used for continuous variables and the χ 2 test or Fisher exact test for categorical variables as appropriate. Comparisons were made between the STRATIS and SEER populations using nominal overall data and then adjusted for baseline characteristics, including age, baseline NIHSS, sex, location of occlusion, time from stroke onset to arrival at the enrolling hospital, Alberta Stroke Program Early CT Score, and delivery (yes/no) of intravenous tissue-type plasminogen activator (IV-tPA). For adjusted models with binary or ordinal outcomes, logistic regression was used for comparisons among groups; in particular, the effect of time to treatment on outcomes was evaluated via binary logistic regression with the incidence of mRS 0 to 2 as outcome and time from emergency medical services (EMS) arrival to arterial puncture as the predictor of interest, with age, NIHSS at baseline, and vessel of occlusion location as covariates. The odds ratio and confidence interval were derived along with the corresponding P value. For mortality, a sensitivity analysis using the method of Rubin 11 was conducted to evaluate the effect of missingness on reported outcomes, including age, NIHSS, Alberta Stroke Program Early CT Score, and occlusion location as baseline characteristics, along with time from onset to puncture and discharge mRS as predictors of the missing data. All statistical tests were 2-sided, with P values <0.05 considered statistically significant. Statistical analyses were conducted in SAS version 9.2 or above (SAS Institute, Cary, NC) and R version 3.2 or above (R Foundation for Statistical Computing, Vienna, Austria).
Results
From August 2014 to June 2016, 1000 patients were enrolled at 55 US centers. Sixteen patients were identified to be screen failures and excluded from the analysis, resulting in a total of 984 patients included in the intent-to-treat analysis population. Patient disposition is presented in Figure I in the onlineonly Data Supplement.
Baseline demographic and clinical characteristics are presented in Table 1 . The mean age was 67.8 years, and 54.2% were male. The median initial qualifying NIHSS score was 17. Most patients had no significant prestroke functional disability. A total of 64.0% of patients received treatment with IV-tPA.
45.2% of patients were transferred from another facility to an enrolling hospital. The mean distance from EMS scene to enrolling hospital was 29 miles (median 14 miles), with 65.2% of patients incurring their stroke within <25 miles from an enrolling hospital. The median times from onset to arrival at the enrolling hospital (door), DTP, and PTR were 138, 72, and 36 minutes, respectively. High enrolling centers (≥30 patients) achieved significantly shorter median DTP times, 67 versus 86 minutes (P<0.001).
The location of target occlusions (ie, vessel treated on first device pass) are presented in Table 1 . Tandem occlusions, defined as cases in which an extracranial lesion accompanied the principal lesion treated, were reported in 14.9% (147/984) of patients. Solitaire was the first MT device used in 96.9% and Mindframe in 3.1% of patients.
The median time from puncture to imaging core labassessed substantial reperfusion (mTICI ≥2b; PTR) was 37 minutes. Core laboratory-assessed substantial reperfusion was achieved in 87.9% (724/824) of cases with evaluable postprocedure angiograms. Emboli to new vascular territory were observed in 0.8% (7/824) of patients. At 24-hour followup, the incidence of sICH was 1.4% (12/841).
At 90-day follow-up, good functional outcome (mRS score 0-2) was achieved in 56.5% (512/906) of patients and excellent functional outcome (mRS score 0-1) in 43.2% (391/906). Ninety-day outcomes could not be obtained in 78 patients.
Increased time from EMS arrival at stroke scene to puncture was associated with a reduced likelihood of good functional outcome at 90 days (P=0.004; Figure 1) , with an associated odds ratio of 0.79 (95% confidence interval, 0.68-0.93) per hour of delay in a model adjusting for age, NIHSS at baseline, and occlusion location. A summary of baseline characteristics and outcomes by time from EMS arrival at stroke scene to puncture is presented in Table II in the online-only Data 
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Supplement. For sensitivity purposes, models using other sets of baseline covariates along with time were assessed, with similar results as presented in Table III in the online-only Data Supplement.
The incidence of neurological deterioration events was 9.2%. The incidence of site-reported study device-related and index procedure-related serious adverse events was 0.2% (2/984) and 1.7% (17/984), respectively. A summary of the serious adverse events is included in Table IV in the onlineonly Data Supplement.
Overall, the all-cause mortality rate ≤90-day follow up was 14.4% (142/984). As a sensitivity analysis, multiple imputation was performed for subjects missing 90-day mRS scores (n=78/984 or 7.9%). The resulting overall 90-day mortality rate of 15.3% from the imputation model 11 was similar to the raw rate of 14.4% based on available data.
Among patients who achieved substantial reperfusion per the adjudication of the imaging core laboratory, favorable outcomes were observed. Good functional outcome was achieved in 60.0% of substantial reperfusers versus 40.4% of nonreperfusers (P<0.001), and mortality was 12.7% in substantial reperfusers versus 23.0% in nonreperfusers (P=0.008).
Comparison With Recent Stent-Retriever Randomized Controlled Trials
Comparing the STRATIS population with the SEER intervention group (n=401), 8 significant differences were observed in several baseline characteristics and time metrics. STRATIS enrolled patients of similar age but with significantly greater proportion of vascular risk factors, significantly higher mean baseline neurological deficit, and fewer patients treated with IV-tPA compared with the SEER intervention group (Tables 1  and 2 ). The median time from onset to arrival at enrolling hospital was significantly longer in STRATIS, whereas the median times from onset to IV-tPA initiation, onset to puncture, enrolling hospital arrival to puncture, and onset to revascularization were significantly shorter in STRATIS.
In unadjusted analysis, the rate of substantial reperfusion was significantly higher in STRATIS (87.9% versus 76.6%; P<0.001). The rate of good functional outcome (mRS score 0-2) was similar between study populations (56.5% versus 54.0%; P=0.43), while the rate of excellent functional outcome (mRS score 0-1) was significantly higher in STRATIS (43.2% versus 35.8%; P=0.01). When adjusted for baseline characteristics, these patterns of outcome persisted while the overall distribution of mRS at 90 days (via the shift test) was significantly more favorable in STRATIS than in SEER (common odds ratio, 1.38; 95% confidence interval, 1.11-1.71; P=0.004). Figure 2 shows the distribution of mRS scores at 90 days. Mortality rate and incidence of sICH were similar between study populations in both unadjusted and adjusted analysis.
Subgroups
Age
Analysis by age showed less favorable rates of clinical outcome with increasing age. Rates of good functional outcome decreased for each 5-year increment of age from <65 to >90 years from 64.3% to 26.5% (P<0.001), while mortality increased from 7.9% to 35.1% (P<0.001; Table V in the online-only Data Supplement).
Seven-to Eight-Hour Window
In an analysis of a subset of patients outside of American Heart Association/American Stroke Association guidelines, patients treated between 6 and 8 hours (n=119) from onset to puncture achieved similar rates of substantial reperfusion, good functional outcome, and mortality compared with those treated within 6 hours (Table VI in the online-only Data Supplement).
Distal Occlusions
When compared with M1 occlusions, substantial reperfusion was achieved less often in M2 occlusions; however, similar rates of good functional outcome and mortality were observed (Table VII in the online-only Data Supplement).
Perfusion Imaging
Perfusion imaging was performed in 378 patients. When compared with patients who did not undergo perfusion imaging (PI−), the patients who underwent perfusion imaging (PI+) had a significantly lower NIHSS and were more directly admitted, but the onset to door and onset to puncture times were similar. The rate of good functional outcome was 62.2% in PI+ patients versus 53.0% in PI− patients (P<0.001; Table  VIII in the online-only Data Supplement). 
Tandem Occlusion
Eighty out of 147 patients who had a tandem occlusion underwent carotid stenting. The median PTR was significantly longer in patients with tandem occlusion (52.5 versus 34 minutes; P<0.001). Significantly more patients with tandem occlusion received IV-tPA. Similar rates of good functional outcome and sICH were observed. Mortality was numerically lower in the tandem occlusion group (11.7% versus 16.4%; P=0.20; Table  IX in the online-only Data Supplement).
Discussion
We report the largest prospectively collected registry of patients undergoing thrombectomy with Solitaire. STRATIS demonstrates that MT can be safely performed in the community with similar process metrics and clinical outcomes to those observed in the randomized trials. 56.5% of patients achieved an mRS score of 0 to 2 at 90 days, while the rate of successful reperfusion (mTICI 2b-3) was 87.9% and 90-day all-cause mortality was 14.4%. sICH occurred in 1.4% of patients.
There was a significantly longer median time from symptom onset to arrival at the enrolling hospital in STRATIS compared with SEER (138.0 versus 104.5 minutes; P=0.03); however, the median time from stroke onset to puncture was 17 minutes shorter in STRATIS, primarily driven by a significantly shorter median DTP time (93 versus 72 minutes; P<0.001). This decrease may suggest an increasing awareness on the importance of rapid hospital workflow since publication of the SEER trials.
The time from EMS scene arrival to puncture, or the system of care interval, is highly dependent on geography, EMS organization, and hospital process. In STRATIS, the median system of care interval was 152 minutes. Each hour of delay was associated with a 5.5% absolute decline in the likelihood of achieving good outcome (mRS score 0-2; Figure 1 ) or number needed to harm of 18. 45.2% of patients were transferred from another facility to the enrolling hospital, even though 65% of patients incurred their stroke within 25 miles from the enrolling hospital (Figure 3) .
The median EMS scene arrival to enrolling hospital arrival time interval was as long as the median DTP time, outlining importance to optimize processes both inside and outside the hospital. High enrollment volume (≥30 patients) was associated with a statistically shorter DTP interval with a trend toward better functional outcome, which replicates the experience of trauma and cardiac centers. 12, 13 There is extensive discussion on how to best avoid transfers to an intervention-capable hospital. Multiple EMS systems have already adopted policies to transport directly to an intervention-capable hospital, either based on a field severity score or for all patients to avoid the delays associated with secondary hospital to hospital transfers. 14, 15 Perfusion imaging resulted in an increase in average DTP time of 15.7 minutes. However, despite this delay, perfusion imaging was associated with significantly higher rates of good clinical outcomes. Further analysis is needed to understand the causes of this association, which may include better selection of patients with mismatch, use of perfusion in higher volume centers, or other factors. Our finding will reinvigorate the ongoing discussion about the benefits of perfusion imaging against the impact of associated time delay in the selection of patients with salvageable tissue.
Technical outcomes were statistically significantly superior in STRATIS with more patients achieving mTICI 2b-3 reperfusion, confirming that the results of these trials can be reproduced-and even improved-in the community. Significantly more patients in STRATIS achieved near normal functional outcome. It should be noted that the site-reported TICI scores 
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October 2017 overestimated the reperfusion success (Table X in the onlineonly Data Supplement). This needs to be taken into account when comparing to other, non-core laboratory adjudicated, registries. Patients with distal occlusions (M2 and distal) did not differ in functional outcome or mortality. This experience corroborates findings of a recent large retrospective analysis of distal occlusions. 16 Within the STRATIS cohort, patients treated beyond the current guideline recommendation between 6 and 8 hours from symptom onset achieved the same rate of good clinical outcomes as patients treated within 6 hours from onset, suggesting that treatment beyond 6 hours may be considered.
STRATIS enrolled patients with tandem extra-and intracranial occlusions. In patients with tandem lesions, the median PTR interval was 18.5 minutes longer than in those without, but rates of good reperfusion and good functional outcomes were similar in patients with and without tandem occlusion. There was no evidence of sICH or higher mortality even with a high portion of systemically thrombolyzed patients. The frequency of good functional outcomes in patients with tandem lesions was similar. Treatment of tandem occlusions may, therefore, be reasonable.
At this point, the benefit of MT in an older population is not well understood. Two out of the 4 SEER trials excluded patients >80 years. In STRATIS, there was no specified age cutoff. The mean age in STRATIS is numerically higher than that in the SEER cohort and slightly lower than that reported in Get With The Guidelines-Stroke registry of lower 70s. 17, 18 Even though the PTR times were similar, there was a statistically significant decline of good outcome by age in STRATIS, *Adjusted for baseline covariates, including age, NIHSS, sex, ASPECTS, site of occlusion, IV-tPA yes/no, and time from onset to door. †Imaging core laboratory received and read angiograms for 846 patients, of whom 22 were not evaluable for reperfusion status, resulting in 824 evaluable angiograms. ‡Any event causing neurological deterioration (≥4 points worsening from baseline on the NIHSS scale). §Defined as any parenchymal hematoma type 1, parenchymal hematoma type 2, remote intraparenchymal hemorrhage, or intraventricular hemorrhage per imaging core laboratory and associated with a ≥4 points worsening on the NIHSS scale within 24 hours.
with only 26% of patients ≥90 years achieving functional independence, but no inference can be made concerning the treatment effect. Further randomized studies are needed to assess the benefit and the cost-effectiveness of MT in the older population.
Limitations
Our study has limitations. First, STRATIS is a single-arm, prospective, postmarket registry and does not include a control arm. However, the study represents the largest cohort published to date reporting outcomes of on label stent-retriever MT. In addition, to minimize bias on Alberta Stroke Program Early CT Score and TICI scoring and improve adjudication of complications, STRATIS used 2 core laboratories and a Clinical Events Committee. Second, the interpretation of reported outcomes in the subgroups analyzed should be viewed with caution because the study did not include any active comparator groups. Finally, the documentation of prehospital time intervals proved to be challenging and is associated with a higher level of data loss, limiting the interpretation of the data. Seventy-eight patients could not be contacted for assessment of 90-day outcome. Baseline characteristics, reperfusion success, and mRS at discharge were similar or better in the cohort with missing 90-day outcome, suggesting that those patients would have had similar or better outcomes (Table XI in 
Conclusions
STRATIS reports the largest to date cohort of patients who underwent thrombectomy with a stent retriever in community and academic hospitals. Despite enrolling a population with higher mean neurological deficit and more risk factors than SEER, results demonstrate that MT with Solitaire is both safe and effective and that the technical and clinical outcomes of the landmark trials using the same device cannot only be reproduced but exceeded. The mean DTP intervals could be reduced by 34%. Every hour of delay in the system of care interval from EMS scene arrival to puncture was associated with a 5.5% absolute decline in achieving good functional outcome. The clinical outcomes seem to be similar for patients with tandem occlusions. This corroborates findings from randomized studies that a treatment benefit exists for these patients. Our findings of similar clinical outcomes in the subpopulations treated between 6 and 8 hours from symptom onset compared with those treated within 6 hours and with distal occlusions compared with proximal occlusions support the conduct of randomized trials for these indications.
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